Management of spasticity in stroke

被引:71
作者
Bhakta, BB [1 ]
机构
[1] Univ Leeds, Sch Med, Rheumatol & Rehabil Res Unit, Leeds LS2 9NZ, W Yorkshire, England
关键词
D O I
10.1258/0007142001903111
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Spasticity treatment must be considered in relation to other impairments with functional goals defined prior to intervention. The effects of muscle co-contraction and involuntary limb movement associated with exaggerated cutaneous reflexes or effort as well as stretch reflex hyperexcitability need to be considered. Exacerbating factors such as pain must be identified. Physical therapy and conventional orthoses are the mainstays of spasticity management during acute rehabilitation. Botulinum toxin shows promise but needs further evaluation in the context of acute rehabilitation. Phenol chemodenervation can produce good results in spasticity refractory to standard treatments. Muscle strengthening exercises may be appropriate in chronic hemiparesis without adversely affecting tone. Electrical stimulation may be a useful adjunct to other spasticity treatments. Difficulty demonstrating functional benefit from antispasticity treatment may imply that interventions directed at single motor impairments whether weakness or spasticity are not; likely to result in functional benefit, but it is their combination that is important.
引用
收藏
页码:476 / 485
页数:10
相关论文
共 28 条
[1]   RECIPROCAL INHIBITION BETWEEN FOREARM MUSCLES IN SPASTIC HEMIPLEGIA [J].
ARTIEDA, J ;
QUESADA, P ;
OBESO, JA .
NEUROLOGY, 1991, 41 (02) :286-289
[2]  
BASMAJIAN JV, 1987, ARCH PHYS MED REHAB, V68, P267
[3]   A MULTI-CENTRE, DOUBLE-BLIND TRIAL OF TIZANIDINE, A NEW ANTISPASTIC AGENT, IN SPASTICITY ASSOCIATED WITH HEMIPLEGIA [J].
BES, A ;
EYSSETTE, M ;
PIERROTDESEILLIGNY, E ;
ROHMER, F ;
WARTER, JM .
CURRENT MEDICAL RESEARCH AND OPINION, 1988, 10 (10) :709-718
[4]   Use of botulinum toxin in stroke patients with severe upper limb spasticity [J].
Bhakta, BB ;
Cozens, JA ;
Bamford, JM ;
Chamberlain, MA .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1996, 61 (01) :30-35
[5]   BOTULINUM NEUROTOXIN-A SELECTIVELY CLEAVES THE SYNAPTIC PROTEIN SNAP-25 [J].
BLASI, J ;
CHAPMAN, ER ;
LINK, E ;
BINZ, T ;
YAMASAKI, S ;
DECAMILLI, P ;
SUDHOF, TC ;
NIEMANN, H ;
JAHN, R .
NATURE, 1993, 365 (6442) :160-163
[6]  
Bobath B., 1990, Adult Hemiplegia: Evaluation and Treatment
[7]   PATHOPHYSIOLOGY OF SPASTICITY [J].
BROWN, P .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1994, 57 (07) :773-777
[8]  
BRUNNSTROM S., 1970, MOVEMENT THERAPY HEM
[9]   A randomised, double blind, placebo controlled trial of botulinum toxin in the treatment of spastic foot in hemiparetic patients [J].
Burbaud, P ;
Wiart, L ;
Dubos, JL ;
Gaujard, E ;
Debelleix, X ;
Joseph, PA ;
Mazaux, JM ;
Bioulac, B ;
Barat, M ;
Lagueny, A .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1996, 61 (03) :265-269
[10]   The effects of common peroneal stimulation on the effort and speed of walking: a randomized controlled trial with chronic hemiplegic patients [J].
Burridge, JH ;
Taylor, PN ;
Hagan, SA ;
Wood, DE ;
Swain, ID .
CLINICAL REHABILITATION, 1997, 11 (03) :201-210